05/10/23 5:30 PMNasdaq : DBVT clinical trialDBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in ToddlersMontrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT TM ) withRHEA-AIneutral
05/09/23 4:30 PMNasdaq : DBVT conferencesDBV Technologies to Participate in Upcoming Investor ConferenceMontrouge, France, May 9, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life SciencesRHEA-AIneutral
05/04/23 4:30 PMNasdaq : DBVT earningsDBV Technologies Reports First Quarter 2023 Financial ResultsMontrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, todayRHEA-AIneutral
04/19/23 5:09 PMNasdaq : DBVT DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDAMontrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint and didRHEA-AIvery positive
04/12/23 4:30 PMNasdaq : DBVT DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General MeetingMontrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceuticalRHEA-AIneutral
03/24/23 4:30 PMNasdaq : DBVT Ordinary and Extraordinary General Meeting of April 12, 2023Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceuticalRHEA-AIneutral
03/13/23 1:30 AMNasdaq : DBVT DBV Technologies UpdateMontrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank. About DBV TechnologiesRHEA-AIneutral
03/07/23 4:30 PMNasdaq : DBVT clinical trialDBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years OldMontrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screen ed in VITESSE Phase 3 Clinical Trial in Peanut - Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois VITESSE is DBV’s Phase 3 clinical study evaluating theRHEA-AIneutral
03/02/23 5:30 PMNasdaq : DBVT DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration DocumentMontrouge, France, March 2, 2023 DBV Techn ologies a nnounces f iling of 202 2 Annual Report on Form 10-K and 202 2 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), todayRHEA-AIneutral
03/02/23 4:30 PMNasdaq : DBVT earningsDBV Technologies Reports Full Year 2022 Financial Results and Business UpdateMontrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old DBV had $209.2 million inRHEA-AIneutral